A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/21/2002	US20020173549 Compositions and methods for treatment of mild cognitive impairment
11/21/2002	US20020173547 Pharmaceuticals compositions
11/21/2002	US20020173546 Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use
11/21/2002	US20020173544 Therapy for kidney disease; complexing calcium acetate with phosphorus
11/21/2002	US20020173540 Using plant extract
11/21/2002	US20020173539 Administering alpha-pyrone compound
11/21/2002	US20020173538 Method for sensitizing cancer cells to cancer therapies with a mevalonate-reducing compound
11/21/2002	US20020173537 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
11/21/2002	US20020173535 Drug abruse; psychological disorders
11/21/2002	US20020173534 Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
11/21/2002	US20020173533 Induce apoptosis; dissolving in critical fluid; separation
11/21/2002	US20020173532 Induce apoptosis
11/21/2002	US20020173531 Central nervous system disorders; psychological disorders
11/21/2002	US20020173530 Single morphic forms of metalloproteinase inhibitors
11/21/2002	US20020173529 Fungicide active substance combinations
11/21/2002	US20020173528 Agonists specific for the peripheral cannabinoid receptor
11/21/2002	US20020173527 Tumor necrosis factor antagonist; antiinflammatory agents
11/21/2002	US20020173525 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
11/21/2002	US20020173524 Modulation of CCR4 function
11/21/2002	US20020173523 Immunosuppression by photochemotherapy
11/21/2002	US20020173522 Pharmaceutical compositions comprising norastemizole
11/21/2002	US20020173521 Inhibitors of copper-containing amine oxidases
11/21/2002	US20020173518 Anticoagulant in mammls
11/21/2002	US20020173517 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure
11/21/2002	US20020173516 Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye
11/21/2002	US20020173515 Antiproliferative agents
11/21/2002	US20020173514 Pyridine-substituted pyrazolopyridine derivatives
11/21/2002	US20020173513 5HT1a Receptor subtype agonist
11/21/2002	US20020173512 Psychological disorders; antidepressants
11/21/2002	US20020173511 Serotonergic compositions and methods for treatment of mild cognitive impairment
11/21/2002	US20020173510 Nutrient mixture; fatty acid, calcium compound and vitamins
11/21/2002	US20020173507 Antiproliferative agents; apoptosis; anticancer agents
11/21/2002	US20020173506 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists
11/21/2002	US20020173505 Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders
11/21/2002	US20020173504 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
11/21/2002	US20020173503 Substituted pyridoindoles as serotonin agonists and antagonists
11/21/2002	US20020173500 Hypotensive agents; antiischemic agents
11/21/2002	US20020173499 Estrogen replacement therapy
11/21/2002	US20020173498 Topical administering; skin disorders
11/21/2002	US20020173496 Formulation containing novel anti-inflammatory androstane derivative
11/21/2002	US20020173495 Selective androgen receptor modulators and methods of use thereof
11/21/2002	US20020173491 Viricides; drug resistance mixtures
11/21/2002	US20020173490 Antidiabetic agents
11/21/2002	US20020173489 Compositions containing a mixture of phosphorous compounds and alkylglycerols
11/21/2002	US20020173488 Boronic Ester and acid compounds, synthesis and uses
11/21/2002	US20020173487 Cyclodextrin-drospirenone inclusion complexes
11/21/2002	US20020173486 Methods for increasing bulk density of chondroitin
11/21/2002	US20020173485 Mixture of hyaluronic acid and polyvinylpyrrolidone
11/21/2002	US20020173484 Ingestion of hyaluronic acid for improved joint function and health
11/21/2002	US20020173483 Blocking adhesion to mammal cells; prevention infections
11/21/2002	US20020173482 Antitumor, anticancer agents
11/21/2002	US20020173479 Administering genes to suppress cancer
11/21/2002	US20020173475 Methods to inhibit viral replication
11/21/2002	US20020173472 Pharmaceutical formulations of resveratrol
11/21/2002	US20020173471 Anticancer agents
11/21/2002	US20020173470 Jasmonate pharmaceutical composition for treatment of cancer
11/21/2002	US20020173466 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
11/21/2002	US20020173461 Methods for enhancing the efficacy of cancer therapy
11/21/2002	US20020173450 Therapeutic intervention to mimic the effect of caloric restriction
11/21/2002	US20020173448 Method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
11/21/2002	US20020173447 Antitumor, anticancer agents
11/21/2002	US20020173446 Viricides
11/21/2002	US20020173445 Selective androgen receptor modulators and methods for their identification, design and use
11/21/2002	US20020173031 Amplification or reduction of drug resistance in bacteria, yeast, plant of mamalian cells; obtain cell, adjust adenosine triphosphate gradient, monitor drug resistance
11/21/2002	US20020173012 Process for the preparation of pharmaceutically acceptable salts of (R,S)-S-adenosyl-L-methionine
11/21/2002	US20020172999 Novel KIAA1061-like cell adhesion molecule-like proteins and polynucleotides encoding them
11/21/2002	US20020172962 Generation of nucleotide sequence ligands; obtain nucleotide sequences mixture, separate nucleotide sequences, amplify nucleotide sequences, incubate with modulator, detect adjustment in binding activity
11/21/2002	US20020172958 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
11/21/2002	US20020172941 Inducing immune response against feline immunodeficiency virus; obtain animal, administer protective agent, detect immunological response against viral infection
11/21/2002	US20020172937 Rapid assay for arthopod-borne disease vectors and pathogens
11/21/2002	US20020172732 Composition comprising cocoa
11/21/2002	US20020172731 Collecting and processing parts of Salvadora persica, preparing a crude extract; testing crude extract; fractionating; isolating, column chromatography, analysis by spectroscopy
11/21/2002	US20020172730 Taste and enhances Noni metabolism and absorption; for use in therapy
11/21/2002	US20020172729 Pharmaceutical composition for stabilising atherosclerotic plaques
11/21/2002	US20020172728 Administering to the woman an effective amount of an herbal extract wherein an active ingredient in herbal extract is galanthamine for improving estrogen-deficiency related neurodegeneration and cognitive dysfunction
11/21/2002	US20020172721 Vitamin formulation for cardiovascular health
11/21/2002	US20020172714 Pharmaceutical preparations and methods for their regional administration
11/21/2002	US20020172693 prostaglandin F analogs, such as 13,14-dihydro-15-(2-benzathiozolyl) pentanor Prostaglandin F1 alpha, with other hair growth stimulant; topically to the skin; can arrest hair loss, reverse hair loss, and promote hair growth; cosmetics
11/21/2002	US20020172678 For regulating cellular proliferation and chemotaxis
11/21/2002	US20020172663 Localized myocardial injection method for treating ischemic myocardium
11/21/2002	US20020172659 Methods and materials for treating inflammatory diseases
11/21/2002	US20020172654 Cosmetic or pharmaceutical compositions comprising homopolymers and salts thereof
11/21/2002	US20020172649 Pharmaceutical composition
11/21/2002	US20020172645 Administering aerosolized thiocyanate for therapy of lung infection in a primate suffering from cystic fibrosis
11/21/2002	US20020172644 Nasal retention of medicaments in the nasal cavity for enhanced topical or systemic activity; therapy
11/21/2002	DE10124475A1 Cosmetic or dermatological composition containing ketohexose, useful for treating e.g. inflammation, pigment disorders, and skin aging, promotes barrier function
11/21/2002	DE10124332A1 Kosmetische oder pharmazeutische Zubereitungen, die Enaminotriazine als Lichtschutzmittel enthalten und neue Enaminotriazine Cosmetic or pharmaceutical preparations containing enaminotriazines as light stabilizers and new enaminotriazines
11/21/2002	DE10123952A1 New naphtho-1,2-thiazine compounds, useful as neuroprotectants for treating e.g. epilepsy or Alzheimer's disease, are allosteric modulators of AMPA receptors
11/21/2002	DE10123503A1 Use of Belamcanda chinensis extract, or its active ingredient, for treating sex hormone-dependent urogenital disorders and prostatic hyperplasia
11/21/2002	DE10122715A1 Verwendung von Rutinen und Aescinen zur Behandlung aurikulärer Durchblutungsstörungen Use of rutins and Aescinen for treating auricular circulatory disorders
11/21/2002	DE10122714A1 Combination of a rutin and aescin for treating ocular disorders associated with altered blood circulation, e.g. glaucoma or edema
11/21/2002	CA2778114A1 Abuse-resistant opioid dosage form
11/21/2002	CA2740056A1 Methods and compositions for treating mammalian nerve tissue injuries
11/21/2002	CA2689808A1 Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
11/21/2002	CA2460603A1 Unigene unidirectional antisense library
11/21/2002	CA2451116A1 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
11/21/2002	CA2449188A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors
11/21/2002	CA2448195A1 Minoxidil-containing liquid composition
11/21/2002	CA2447588A1 Dihydroimidazo [5,1-a]-$g(b)-carboline derivatives, method for preparing same and use thereof as medicine
11/21/2002	CA2447574A1 Oxidized collagen formulations for use with non-compatible pharmaceutical agents

1 ... 5644 5645 5646 5647 5648 5649 5650 5651 5652 5653 5654 5655 5656 5657 5658 5659 5660 5661 5662 5663 5664 ... 7860